Global /South Korea /Healthcare /Drug Manufacturers - General /326030

SK Biopharmaceuticals Co., Ltd.

326030

• KRX: 326030 • Delayed

99,900KRW -1.9%

65.21 USD

As of 24 June 2026, SK Biopharmaceuticals Co., Ltd. has a market cap of $5.2B USD, ranking #3665 globally and #91 in South Korea. It ranks #285 in the Healthcare sector, and #108 in the Drug Manufacturers - General industry.

Global Rank

3665

Country Rank

Sector Rank

285

Industry Rank

108

Key Stats

Market Cap

$5.2BUSD

7.97T KRW

Enterprise Value

$5.04BUSD

7.72T KRW

Revenue (TTM)

$460.73MUSD

706.74B KRW

EBITDA (TTM)

$144.19MUSD

220.89B KRW

Net Income (TTM)

$174.03MUSD

266.95B KRW

EBITDA Margin

31%

Profit Margin

38%

PE Ratio

29.9

Forward PE

29.9

PS Ratio

11.3

PB Ratio

9.6

EV/EBITDA

41.4

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Dong Hoon Lee open_in_new

Employees

246

Founded

1993

Website

skbp.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.9%	-2%	1.1%	-15%	-13%	-19%	-2.8%	47%	-12%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	326030 SK바이오팜(주) Ordinary Shares ISIN: KR7326030004 Shares Out.: Shares Outstanding: 78.313M¹ Shares Float: 39.016M² TV: TradingView: KRX: 326030 SA: Stock Analysis: KRX: 326030 YF: Yahoo Finance: 326030.KS GF: Google Finance: KRX: 326030 BA: Barron's: 326030 MS: Morningstar: XKRX: 326030	99,900 KRW	TV: TradingView: KRX: 326030 SA: Stock Analysis: KRX: 326030 YF: Yahoo Finance: 326030.KS GF: Google Finance: KRX: 326030 BA: Barron's: 326030 MS: Morningstar: XKRX: 326030

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.07B 13.91T KRW 74%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.72B 10.3T KRW 29%	1958.1	South Korea
ABL Bio Inc. KRX: 298380	$4.92B 7.55T KRW -5.3%	-	South Korea
Yuhan Corp. KRX: 000100	$4.51B 6.92T KRW -13%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.41B 6.76T KRW -15%	-	South Korea
Hanmi Pharm. Co., Ltd. KRX: 128940	$3.99B 6.12T KRW -23%	36.1	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 15K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 10K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 7K%	97.4	United States
Roche Holding AG SIX: RO	$316.71B 256.25B CHF 6K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$285.49B 215.59B GBP 5K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 5K%	15.1	United States

chevron_leftBack